0001437749-22-029969.txt : 20221230
0001437749-22-029969.hdr.sgml : 20221230
20221230202125
ACCESSION NUMBER: 0001437749-22-029969
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221216
FILED AS OF DATE: 20221230
DATE AS OF CHANGE: 20221230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Phillip E
CENTRAL INDEX KEY: 0001959565
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35285
FILM NUMBER: 221503049
MAIL ADDRESS:
STREET 1: C/O VAXART, INC.
STREET 2: 170 HARBOR WAY, STE. 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxart, Inc.
CENTRAL INDEX KEY: 0000072444
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 591212264
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 550-3500
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Aviragen Therapeutics, Inc.
DATE OF NAME CHANGE: 20160413
FORMER COMPANY:
FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20121113
FORMER COMPANY:
FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS
DATE OF NAME CHANGE: 20100719
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-12-16
0000072444
Vaxart, Inc.
VXRT
0001959565
Lee Phillip E
C/O VAXART, INC.
170 HARBOR WAY, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
Chief Financial Officer
Common Stock
2022-12-16
4
A
0
68750
0
A
68750
D
Stock Option (Right to Buy)
1.06
2022-12-16
4
A
0
412500
0
A
2032-12-15
Common Stock
412500
412500
D
Grant of shares upon vesting of restricted stock units ("RSUs"). The RSUs vest as to 25% of the shares underlying the award on each anniversary of December 15, 2022 (the "Start Date"), so that the RSUs would be fully vested on the fourth anniversary of the Start Date.
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on December 15,2023, the first anniversary of the Start Date, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on December 16, 2026.
/s/ Edward Berg, Attorney-in-Fact for W. Mark Watson
2022-12-28